CognitOss, discovered by Locate Bio, for the treatment of chronic osteomyelitis. The device is inits development stage for the treatment of chronic osteomyelitis.
CognitOssis a fully resorbable bone graft built with best-in-class bone healing properties and a proprietary dual-phasic release of antibiotics will provide a bolus release at the site of the infection by preventing re-infection through a further controlled release. It is used as an adjuvant to oral or intravenous antibiotics to prevent colonisation of the graft material.
CognitOss expands the capabilities of the bone graft with a new reactive antibiotic release mechanismreleasinghigher levels of antibiotic in the presence of infection. In addition, it offers the surgeons a single surgical procedure alternative.
Osteomyelitis is an inflammatory infection of the bone which is generally caused by bacteria. The current standard treatment available for chronic osteomyelitis is surgical debridement, long-term, and high-dose administration of antibiotics. Moreover, for larger defectsbone grafting is the procedure which often requires a second surgical process to remove the non-resorbable bone graft.
US Food and Drug Administration (FDA)has granted Breakthrough Device Designation for CognitOss designed for the treatment of chronic osteomyelitis.